MiNK Therapeutics, Inc.
INKT
$14.57
-$0.33-2.22%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 45.50% | 57.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.62% | -42.01% | |||
| Operating Income | -45.62% | 42.01% | |||
| Income Before Tax | -53.17% | -12.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -53.17% | -12.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -53.17% | -12.33% | |||
| EBIT | -45.62% | 42.01% | |||
| EBITDA | -46.64% | 41.73% | |||
| EPS Basic | -52.51% | -12.10% | |||
| Normalized Basic EPS | -48.44% | 36.80% | |||
| EPS Diluted | -52.51% | 44.03% | |||
| Normalized Diluted EPS | -48.44% | 36.80% | |||
| Average Basic Shares Outstanding | 0.43% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.43% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||